肾脏疾病、高血压治疗与脑灌注及结构
SPRINT试验神经影像亚组纳入716例高血压患者,随机接受强化(收缩压<120 mmHg)或标准(<140 mmHg)降压治疗,随访中位3.9年。在早期肾病人群中,强化降压未对脑灌注或结构产生不利影响,支持其脑安全性。
要点
- 强化降压未显著改变整体脑血流量或白质病变体积。
- 在eGFR<60者中,强化降压与整体脑血流量轻度增加相关。
- 在白蛋白尿者中,强化降压与总脑体积轻度减少相关。
核心结论
- 在主要患有早期肾病的高血压成人中,强化与标准降压对脑灌注或结构无不利影响。
- 研究结果支持强化降压目标对早期肾病人群脑健康的安全性。
研究设计与样本
- SPRINT随机试验的神经影像亚组研究。
- 共716例随机参与者,平均年龄68岁,中位随访3.9年后进行影像学检查。
- 基线CKD通过eGFR和UACR评估。
主要发现
- 在eGFR<60 mL/min/1.73 m2者(n=234)中,强化vs标准降压对整体脑血流量变化的影响为3.38(95%CI 0.32-6.44)mL/100 g/min。
- 在eGFR<60者中,对白质病变体积变化的影响为-0.06(95%CI -0.16-0.04)cm3(反双曲正弦转换)。
- 在eGFR<60者中,对总脑体积变化的影响为-3.8(95%CI -8.3-0.7)cm3。
- 在UACR>30 mg/g者(n=151)中,强化vs标准降压对整体脑血流量变化的影响为1.91(95%CI -3.01-6.82)mL/100 g/min。
- 在UACR>30 mg/g者中,对白质病变体积变化的影响为0.003(95%CI -0.13-0.13)cm3(反双曲正弦转换),对总脑体积变化的影响为-7.0(95%CI -13.3--0.3)cm3。
临床怎么用
- 对于早期肾病患者,强化降压至收缩压<120 mmHg未显示脑灌注或结构损害。
- 临床可依据SPRINT方案对早期肾病人群实施强化降压,但需个体化评估。
局限性
- 多中心设计导致测量变异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: The safety of intensive blood pressure (BP) targets is controversial for persons with chronic kidney disease (CKD). We studied the effects of hypertension treatment on cerebral perfusion and structure in individuals with and without CKD. STUDY DESIGN: Neuroimaging substudy of a randomized trial. SETTING & PARTICIPANTS: A subset of participants in the Systolic Blood Pressure Intervention Trial (SPRINT) who underwent brain magnetic resonance imaging studies. Presence of baseline CKD was assessed by estimated glomerular filtration rate (eGFR) and urinary albumin-creatinine ratio (UACR). INTERVENTION: Participants were randomly assigned to intensive (systolic BP <120 mm Hg) versus standard (systolic BP <140 mm Hg) BP lowering. OUTCOMES: The magnetic resonance imaging outcome measures were the 4-year change in global cerebral blood flow (CBF), white matter lesion (WML) volume, and total brain volume (TBV). RESULTS: A total of 716 randomized participants with a mean age of 68 years were enrolled; follow-up imaging occurred after a median 3.9 years. Among participants with eGFR <60 mL/min/1.73 m2 (n = 234), the effects of intensive versus standard BP treatment on change in global CBF, WMLs, and TBV were 3.38 (95% CI, 0.32 to 6.44) mL/100 g/min, -0.06 (95% CI, -0.16 to 0.04) cm3 (inverse hyperbolic sine-transformed), and -3.8 (95% CI, -8.3 to 0.7) cm3, respectively. Among participants with UACR >30 mg/g (n = 151), the effects of intensive versus standard BP treatment on change in global CBF, WMLs, and TBV were 1.91 (95% CI, -3.01 to 6.82) mL/100 g/min, 0.003 (95% CI, -0.13 to 0.13) cm3 (inverse hyperbolic sine-transformed), and -7.0 (95% CI, -13.3 to -0.3) cm3, respectively. The overall treatment effects on CBF and TBV were not modified by baseline eGFR or UACR; however, the effect on WMLs was attenuated in participants with albuminuria (P = 0.04 for interaction). LIMITATIONS: Measurement variability due to multisite design. CONCLUSIONS: Among adults with hypertension who have primarily early kidney disease, intensive versus standard BP treatment did not appear to have a detrimental effect on brain perfusion or structure. The findings support the safety of intensive BP treatment targets on brain health in persons with early kidney disease. FUNDING: SPRINT was funded by the National Institutes of Health (including the National Heart, Lung, and Blood Institute; the National Institute of Diabetes and Digestive and Kidney Diseases; the National Institute on Aging; and the National Institute of Neurological Disorders and Stroke), and this substudy was funded by the National Institutes of Diabetes and Digestive and Kidney Diseases. TRIAL REGISTRATION: SPRINT was registered at ClinicalTrials.gov with study number NCT01206062.
引用
- Kurella Tamura M, Gaussoin S, Pajewski NM, et al. Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure. Am J Kidney Dis. 2021. PMID: 34543687. doi:10.1053/j.ajkd.2021.07.024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。